Kevin DeGeeter

Stock Analyst at Ladenburg Thalmann

(2.86)
# 1,863
Out of 5,044 analysts
45
Total ratings
38.24%
Success rate
55.35%
Average return

Stocks Rated by Kevin DeGeeter

ORIC Pharmaceuticals
Jul 8, 2025
Initiates: Buy
Price Target: $15
Current: $12.93
Upside: +16.01%
Cardiff Oncology
Jul 8, 2025
Initiates: Buy
Price Target: $19
Current: $2.24
Upside: +748.21%
NovoCure
Jul 8, 2025
Initiates: Buy
Price Target: $30
Current: $13.48
Upside: +122.55%
AN2 Therapeutics
Apr 19, 2022
Initiates: Outperform
Price Target: $22
Current: $1.30
Upside: +1,592.31%
Personalis
Feb 25, 2022
Maintains: Outperform
Price Target: $30$24
Current: $9.55
Upside: +151.31%
Fulgent Genetics
Jan 25, 2022
Maintains: Outperform
Price Target: $141$125
Current: $22.73
Upside: +449.93%
MDxHealth
Nov 29, 2021
Initiates: Outperform
Price Target: $18
Current: $4.81
Upside: +274.22%
Sera Prognostics
Nov 19, 2021
Initiates: Outperform
Price Target: $19
Current: $3.49
Upside: +444.41%
Spero Therapeutics
Oct 1, 2021
Downgrades: Perform
Price Target: n/a
Current: $2.33
Upside: -
Palo Alto Networks
Aug 24, 2021
Maintains: Outperform
Price Target: $75$79
Current: $217.16
Upside: -63.54%
Maintains: Outperform
Price Target: $161$155
Current: $62.74
Upside: +147.05%
Downgrades: Perform
Price Target: n/a
Current: $9.38
Upside: -
Initiates: Outperform
Price Target: $25
Current: $9.53
Upside: +162.33%
Initiates: Outperform
Price Target: $1,800
Current: $5.75
Upside: +31,204.35%
Downgrades: Perform
Price Target: n/a
Current: $34.88
Upside: -
Initiates: Outperform
Price Target: n/a
Current: $5.01
Upside: -
Downgrades: Perform
Price Target: n/a
Current: $3.78
Upside: -
Initiates: Outperform
Price Target: $1,500
Current: $3.35
Upside: +44,676.12%
Initiates: Outperform
Price Target: $900
Current: $1.82
Upside: +49,350.55%
Upgrades: Buy
Price Target: n/a
Current: $8.38
Upside: -
Initiates: Buy
Price Target: $165
Current: $12.50
Upside: +1,220.00%
Initiates: Buy
Price Target: $225
Current: $104.68
Upside: +114.94%
Upgrades: Neutral
Price Target: n/a
Current: $7.91
Upside: -
Upgrades: Buy
Price Target: n/a
Current: $2.42
Upside: -